Health · Pharma & Biotech · 1 hr ago
Onconic says OCN-501 preserved muscle in preclinical obesity-drug study
South Korea’s Onconic Therapeutics tested OCN-501 with semaglutide in a preclinical study.
Semaglutide is the active ingredient in Wegovy, an obesity treatment.
The company presented the findings at a US obesity conference in Washington, DC.
The combination group lost 15.3% of body weight, versus 13.1% with semaglutide alone, but that difference was not statistically significant.
Onconic said the combination improved muscle mass and limited loss of muscle strength compared with semaglutide alone.
This matters because the company aims to add muscle preservation to medicines used for obesity.
Onconic plans to develop OCN-501 as a combination treatment with incretin-based drugs such as Wegovy and Mounjaro; the candidate is still being studied before clinical use.
Onconic Therapeutics said preclinical testing found that its candidate OCN-501 helped preserve muscle when used with semaglutide.
The company presented the study at the American Obesity Association’s meeting in Washington, DC, on November 16.
Weight loss was 15.3% with semaglutide and OCN-501 and 13.1% with semaglutide alone, a difference that was not statistically significant.
Onconic said the combination improved muscle mass and restrained declines in muscle strength compared with semaglutide alone.
The company plans to develop OCN-501 as a combination treatment with incretin-based obesity drugs.
- Who
- Onconic Therapeutics conducted the preclinical study.
- What
- The company reported that OCN-501 helped preserve muscle when combined with semaglutide.
- When
- The results were presented on November 16, 2026, and reported by Onconic on November 17.
- Where
- The study results were presented at a meeting in Washington, DC.
- Why
- OCN-501 is being developed to maintain muscle energy metabolism and reduce signals that break down muscle protein.
This story does not have two clearly opposing sides.
Onconic presented the preclinical study results at the American Obesity Association’s meeting in Washington, DC.
Onconic announced that the preclinical study had found OCN-501 effective when combined with an obesity drug.
- Drug candidate
- OCN-501
- Semaglutide-only weight loss
- 13.1%
- Combination weight loss
- 15.3%
- Study location
- Washington, DC
- Presentation date
- November 16, 2026
1 source
What people are saying
We plan to develop OCN-501 as a combination treatment that adds muscle-preserving function to incretin-based obesity drugs such as Wegovy and Mounjaro.